Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company redefining the treatment of autoimmune and ...

Many established medical therapies to treat myasthenia gravis remain in use, and newer options are available for patients who ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

On June 16, 2025, RemeGen Co., Ltd. ('RemeGen', stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand ...

Its growth is attributed to the anticipated launch of seven late-stage pipeline therapies. The myasthenia gravis (MG) market ...

The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease ...

People have been let down by a system that continues to put up barriers to accessing treatments that could significantly ...

Bringing this interview with Marla Black Morgan, MD, to a close, she looks to the future of research in both myasthenia ...

Immunovant faces high R&D costs, limited cash runway, and unproven clinical edge despite pipeline progress and deeper IgG ...